EQHealthcare · BiotechnologyEQ Stock Forecast: Equillium, Inc. Price Predictions for 2026-2027
The 9 Wall Street analysts covering Equillium, Inc. hold a median 12-month price target of $7 — +224.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 12 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
EQ stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Equillium, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (92): The shares have been drifting up relative to others.
Volatility (16): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
EQ stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on EQ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +224.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 July 2026 | Piper Sandler | Initiates | Overweight | $20 |
| 2 June 2026 | Roth Capital | Reiterates | Buy | — |
| 28 May 2026 | Leerink Partners | Upgrade | Outperform | — |
| 28 May 2026 | Roth Capital | Reiterates | Buy | — |
| 17 Apr 2026 | Roth Capital | Reiterates | Buy | — |
| 16 Apr 2026 | B. Riley Securities | Initiates | Buy | — |
| 14 Apr 2026 | Raymond James | Initiates | Strong Buy | — |
| 13 Mar 2026 | Roth Capital | Initiates | Buy | — |
| 28 Mar 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 1 Nov 2024 | Jones Trading | Downgrade | Hold | — |
| 19 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Dec 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Nov 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Aug 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 14 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Aug 2023 | HC Wainwright& Co. | Reiterates | Buy | — |
| 15 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EQ appears on the weeks it earns a place.
EQ analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Equillium, Inc. (EQ) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −5.8×
- Price / sales
- —
- Price / book
- 2.4×
- EV / EBITDA
- −3.8×
Cheaper than 90% of US stocks
Cheaper than 41% of US stocks
Cheaper than 77% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 33% of US stocks
Higher than 30% of US stocks
- Return on equity
- −54.4%
- Return on assets
- −31.9%
- Dividend yield
- —
Higher than 20% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
EQ vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Equillium, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about EQ stock
What is the EQ stock price forecast for 2026-2027?
The 9 Wall Street analysts covering Equillium, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is EQ stock a buy right now?
Of the 9 analysts covering Equillium, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Equillium, Inc. 31 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank EQ?
As at 12 Aug 2026, Equillium, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).
Will EQ stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts implies +224.1% from the last close, and Ticker Nerd's factor model ranks Equillium, Inc. 31 out of 100 as at 12 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the EQ stock forecast for 2030?
No analyst covering Equillium, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EQ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $20 over the next 12 months.
How has EQ stock performed over the past year?
Equillium, Inc. returned +132.3% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Equillium, Inc. do?
Equillium, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with significant unmet medical needs.
About Equillium, Inc.
Equillium, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with significant unmet medical needs. The company's lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody currently in phase 3 clinical trials for acute graft-versus-host disease, with additional development in systemic lupus erythematosus and ulcerative colitis. The company also develops EQ101, a selective tri-specific inhibitor targeting multiple interleukin pathways for cutaneous T cell lymphoma treatment, and EQ504, an aryl hydrocarbon receptor modulator being advanced for ulcerative colitis. Equillium serves multiple medical specialties including gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology. The company is advancing its pipeline through strategic financing initiatives and partnerships while maintaining focus on improving capital efficiency and clinical development.
CEO Mr. Bruce Steel · 14 employees · United States · https://www.equilliumbio.com